is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
A recent workshop in Dubai discussed gaps and barriers in care models for most at risk population.
03 April 2019
Experts gathered at a recent workshop ‘HCV Screening and Linkage to Care & Substances Users Practical View’ in Dubai, UAE, to discuss gaps and barriers in care models for most at risk population.
“There are still substantial gaps and barriers for PWID to access testing and treatment. At the same time, because they are the most at risk population, their treatment should be a priority if we want to achieve a goal of elimination of the disease,” explained Dr. Huda Al Quraishi, Senior Specialist of Gastroenterology and Hepatology, Rashid Hospital, Dubai, UAE.
“Namely, if we don’t intervene on time, long-term care following the development of cirrhosis, decompensated liver disease, and liver cancer will add to the existing disease burden.”
The UAE and Kuwait have made major strides in developing interventions that lead towards the elimination of HCV by 2030. To support screening and HCV elimination efforts in the UAE, the Dubai Health Authority (DHA) announced in July 2018 the inclusion of free screening and treatment for Hepatitis C under the basic benefit plan of the Dubai Mandatory Health Insurance Scheme. However, there are still many interventions that can substantially curb the epidemic.
According to Dr. Tarek Abdelgawad, who is the Treatment and Rehabilitation Director at the Abu Dhabi National Rehabilitation Centre, “HCV treatment and care could be delivered in various settings such as hospitals, primary health clinics or drug rehabilitation centers. Experience has shown that multidisciplinary care that offers support for drug dependency, social and psychological services in addition to medical care, have been successful at increasing access to HCV testing and treatment among PWID.”
Development of highly effective direct acting antivirals (DAAs) with efficacy greater than 95 per cent following 8 to 12 weeks treatment have brought significant successes in the elimination of HCV. However, just because a disease is curable, that doesn’t mean that it is defeated if most-at-risk populations, such as PWID are marginalised.